Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...

Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits ...

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.

With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...

BridgeBio Pharma BBIO) stock received a Perform rating from Oppenheimer on market challenges to its late-stage assets acoramidis and infigratinib. Read more here.

Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN ...

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 ...